Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy
Subclinical cholestasis predicted poor progression-free and overall survival in multivariate analyses across six independent immunotherapy-treated cohorts of cancer patients. We postulate that subclinical cholestasis is a proxy of gut dysbiosis and features among the molecular cues of resistance to PD-1 blockade.
Subclinical cholestasis predicted poor progression-free and overall survival in multivariate analyses across six independent immunotherapy-treated cohorts of cancer patients. We postulate that subclinical cholestasis is a proxy of gut dysbiosis and features among the molecular cues of resistance to PD-1 blockade.
Gustave Roussy